January 21, 2026 4:51pm

What a difference sentiment makes for a session!

As funds and investors piled back into C&GT equities after cowering earlier in the week

Having written this a.m., “Time to stay in-place after volatility surged”

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

No Don Quixote as I continually ask, what do all these stock sources, I-Banks and brokers do for you in providing daily information? Availability of data have made intel both complex; I see myself as a collector and my responsibility is to further identify and interpret data to bridge some gaps in an investment decision.

 

RMi Pre-opening: Ricochet … https://www.regmedinvestors.com/articles/14275   

RMi Research Note: Capricor Therapeutics (CAPR) Provides Regulatory Update on Deramiocel BLA… https://www.regmedinvestors.com/articles/14249

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): A new financing attempt? … https://www.regmedinvestors.com/articles/13812

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Wednesday: The Dow closed UP +588.64 points or +1.21%, the S&P closed UP +78.76 points or +1.16% while the Nasdaq closed UP +270.502 points or +1.18%

  • Theme of the session: Trump called off EU tariffs

Wednesday’s (my) 40-company covered sector’s advance/decline line opened positive with 33 incliners, 6 decliners and 1 flat ending with a positive close of 33 incliners, 6 decliners and 1 flat

The CBOE Fear (VIX) index, Wednesday closed at 16.99, after Tuesday’s 20.17, Monday was a holiday, Friday closed at 15.86, Thursday’s 15.95 and last Wednesday’s 16.74

Metrics: Wednesday … another reversal

  • The RUT was up +52.81 points or +2%,
  • The XLV was UP +2.86 points or +1.84%,
  • The NBI was up +140.53 points or +2.43%;
  • The XBI was up +2.89 points or +2.31%
  • The IWM was up +5.19 or +1.98%;
  • The IBB was up +4.44 points or +2.60%,
  • The VIX was down -3.10 points or -15.43% at to 16.99

 

Q1/26 – 2 holidays, 2 neutral, 4 negative and 4 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Wednesday Closing UP (10 of 33) Monday was a holiday

  • Vertex (VRTX +$19.06 after Tuesday’s +$0.72 after Friday’s +$2.44),
  • BioNTech (BNTX +$12.44 after Tuesday’s -$3.44 after Friday’s +$2.93),
  • Alnylam Pharmaceuticals (ALNY +$9.93 after Tuesday’s -$3.46 after Friday’s -$0.33),
  • IQIA Holdings (IQV +$7.65 after Tuesday’s -$4.05 after Friday’s -$3.61),
  • Moderna (MRNA +$6.81 after Tuesday’s +$1.16 after Friday’s +$2.48),
  • Arrowhead Pharmaceuticals (ARWR +$2.32 after Tuesday’s +$1.44 after Friday’s -$2.41),
  • CRISPR Therapeutics (CRSP +$2.12 after Tuesday’s -$0.90 after Friday’s -$0.70),
  • Ionis Pharmaceuticals (IONS +$1.91 after Tuesday’s +$1.20 after Friday’s -$0.88),
  • Vericel (VCEL +$1.43 after Tuesday’s -$1.11 after Friday’s -$1.17),
  • Intellia Therapeutics (NTLA +$1.20 after Tuesday’s +$0.33 after Friday’s +$0.61),

Flat (1)

  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Tuesday’s $0.00)

Wednesday’s Closing DOWN (6 of 6): Monday was a holiday 

  • uniQure NV (QURE -$0.66 after Tuesday’s -$0.44 after Friday’s +$0.84),
  • Supernus Therapeutics (SUPN -$0.30 after Tuesday’s -$0.18),
  • Generation Bio (GBIO -$0.13),
  • MiMedx (MDXG -$0.06),
  • Cellectis SA (CLLS -$0.04),
  • Brainstorm Cell Therapeutics (BCLI -$0.01),

 

The Bottom Line: More of the … WHY

STORY OF THE DAY, I read somewhere, Trump huffed and puffed and, in the end --- got a Greenland deal to protect the US!

  • Calling-off threatened tariffs on European nations, just days after he roiled markets with the threats.
  • After investors rushed for Tuesday’s exits against a background of international insecurity.

For the week:

  • The S&P 500 is down 64.39 points, or 0.9%.
  • The Dow is down 282.10 points, or 0.6%.
  • The Nasdaq is down 290.56 points, or 1.2%.
  • The Russell 2000 is up 20.43 points, or 0.8%.

Moderna (MRNA) stock jumped 11% on Wednesday and Merck (MRK) announced 5-year data for their personalized cancer vaccine that showed the treatment sustained improvements for patients. Merck stock advanced 1.8%.

  • According to the follow-up results, the intismeran autogene, in combination with the drug Keytruda, reduced the risk of recurrence or death by 49% in post-surgery melanoma patients compared to Keytruda alone

 

The recent profit-taking could also foreshadow some of the volatility ahead and …

  • RISK is always a factor remaining and … will boil-up under the surface until or as slight shocks rock the C&GT sector and markets!

As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

  • I would be following share pricing’s ascension on current biotech, cell and gene therapy sector upsides; so, some profiteering can be “situated” while maintaining a position, less elevated!

 

January – 4th week:

  • 1/21 – Wednesday closed positive with 33 incliners, 6 decliners and 1 flat
  • 1/20 - Tuesday closed negative with 16 incliners, 22 decliners and 2 flats
  • 1/19 – Monday was a market holiday, MLK Jr day

January – 3nd week:

  • 1/16 – Friday closed negative with 11 incliners, 28 decliners and 1 flat
  • 1/15 - Thursday closed negative with 8 incliners, 30 decliners and 2 flats
  • 1/14 – Wednesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 1/13 – Tuesday closed neutral with 19 incliners, 19 decliners and 2 flats
  • 1/12 – Monday closed neutral with 19 incliners, 19 decliners and 2 flats

January 2nd week

  • 1/9 - Friday closed negative with 10 incliners, 28 decliners and 2 flats
  • 1/8 – Thursday closed negative with 7 incliners, 30 decliners and 3 flats
  • 1/7 – Wednesday closed positive with 33 incliners, 4 decliners and 2 flats
  • 1/6 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 1 /5 - Monday closed negative with 18 incliners, 21 decliners and 1 flat

January’s 1st week:

  • 1 /2 - Friday closed positive with 18 incliners, 17 decliners and 5 flats
  • 1/1 -Thursday was a holiday, New Years Day

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Wednesday: Vertex (VRTX), BioNTech (BNTX) and IQIA Holdings (IQV),
  • Tuesday: Arrowhead Pharmaceuticals (ARWR), Ionis Therapeutics (IONS) and Moderna (MRNA)
  • Monday was holiday
  • Friday: BioNTech (BNTX), Moderna (MRNA) and Vertex (VRTX)

The worst three (3) in the session: Losers

  • Wednesday: uniQure NV (QURE), Supernus Therapeutics (SUPN) and Ultragenyx Pharmaceuticals (RARE)
  • Tuesday: IQIA Holdings (IQV), Alnylam Pharmaceuticals (ALNY) and BioNTech (BNTX),
  • Monday was holiday
  • Friday: IQIA Holdings (IQV), Arrowhead Pharmaceuticals (ARWR) and Vericel (VCEL)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.